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South Africa (SA) has a high burden of multidrug-resistant 
tuberculosis (MDR-TB), i.e. TB resistant to isoniazid and rifampicin, 
the most effective TB drugs.[1] The current MDR-TB regimen requires 
the use of multiple, toxic, poorly efficacious and expensive second-
line drugs for 18 - 24 months. As a consequence of the often severe 
side-effects and lengthy unpleasant treatment, adherence is poor 
and failure to complete treatment common.[2] Overall, treatment is 
successful in only half the patients treated.[3]
Until 2008 SA, together with many countries in the world, adopted 
an inpatient model of care in which patients were hospitalised for 
the initial 6-month injectable phase of treatment in a centralised 
specialised hospital to facilitate daily injections and allow close 
monitoring of adverse events and adherence. Following discharge, for 
the remaining treatment period (18 months) patients were expected 
to return to the centralised hospital for monthly outpatient visits. 
However, by 2008 the escalating burden of MDR-TB and limited 
bed capacity resulted in long waiting lists, high mortality while 
patients waited to access treatment, and nosocomial transmission.[4-6] 
Furthermore, as the facilities to which patients were discharged were 
unfamiliar with MDR-TB management, continuity of care was poor 
and many patients were lost to follow-up.[7,8]
To address these problems, alternative models of care for MDR-TB 
patients were introduced,[9,10] and in August 2011 a policy framework 
on decentralised and deinstitutionalised management of MDR-TB 
was launched by the National Department of Health (NDoH).[11] In 
late 2015, the World Health Organization (WHO) led a review to 
assess the performance and outcomes of the MDR-TB programme 
and the implementation of alternative models of care.[3] The review 
applauded recent efforts by the NDoH to address the TB and MDR-
TB burden in SA, but also highlighted areas in which MDR-TB 
programme performance could be improved.
For the first time in the modern history of TB control, a shortened 
regimen and new drugs have been become available for the treatment 
of MDR-TB.[12] These advances have revived hope for improved 
patient outcomes and for stopping ongoing transmission of MDR-
TB.[13] In 2013, the WHO recommended the use of a new drug, 
bedaquiline, for MDR-TB, followed by a similar recommendation in 
2014 for the use of delamanid.[14,15] In addition, the use of repurposed 
drugs such as linezolid and clofazimine is being encouraged. These 
new drugs are primarily reserved for MDR-TB patients who have 
additional resistance to second-line drugs or respond poorly to 
the current treatment regimen. However, treatment outcomes are 
also poor for MDR-TB patients without second-line resistance. For 
these patients, hope comes in the form of a shortened standardised 
treatment regimen, conditionally recommended by the WHO in 
May 2016.[16] Subsequently, the NDoH announced that this shorter 9 - 
12-month regimen using existing drugs and repurposed clofazimine 
will be available in SA in the first half of 2017.
Given concern about the development of resistance to new drugs 
and logistical issues in the introduction of new regimen approaches, 
the tendency will be to centralise the provision and management of 
both these initiatives. However, given the burden of MDR-TB in SA 
together with the previous poor performance of centralised care, both 
the new drugs and shortened treatment regimen need to be available 
at centralised and decentralised hospitals and deinstitutionalised 
treatment sites to ensure universal access to effective treatment.
Although MDR-TB is treatable and curable, its programmatic 
management has long been characterised by multiple problems 
and inefficient health systems that fail the patient.[13,17] To ‘seize the 
day’ and capitalise on the window of opportunity afforded by the 
introduction of the shortened regimen and new and repurposed 
drugs, these interventions must be optimally implemented. In this 
editorial we identify the key findings and recommendations from 
the WHO review that need to be addressed to ensure optimal 
implementation of the shortened regimen and new drugs.
Summary of the WHO review findings
While the WHO review of decentralised and deinstitutionalised 
MDR-TB treatment was wide ranging, several key issues were identi-
fied pertinent to implementation of the shortened regimen and new 
drugs.
The review found that, for a number of reasons, the extent and 
co-ordination of decentralised MDR-TB service implementation var-
ied across the provinces. Firstly, the MDR-TB programme was not 
closely aligned to the TB programme or recent NDoH initiatives such 
as re-engineering of primary healthcare (PHC) services or the ‘ideal 
clinic’ initiative. Secondly, different policy and strategy documents 
do not always ‘talk to each other’, and MDR-TB management and the 
decentralisation policy framework are not consistently referred to. 
Importantly, as the framework was not costed, districts were expected 
to implement the framework with no extra resources. As a result, 
implementation and co-ordination of decentralised services varied, 
the framework was seldom included in district operational plans, and 
staffing was often inadequate. Finally, district and provincial level sup-
port and supervision for framework implementation were inadequate.
Quality of clinical care is important both for individual patient 
care and for stewardship of second-line drugs. The review found that 
clinical management was good and had improved over time. However, 
inadequate linkages to care and unclear referral pathways contributed 
to a loss of patients between different levels of care, and suboptimal 
integration of MDR-TB and HIV services compromised treatment. 
Monitoring of adverse events was inadequate, and in 29% of the medical 
records reviewed, patients were not regularly asked about adverse events. 
Adherence support was inadequate, with up to 90% of patients reviewed 
missing doses in both the injectable and continuation phases. Ongoing 
staff training with proper and regular supervision was often lacking, and 
there were no policies for patients failing to respond to treatment.
Several inadequacies in monitoring and evaluation of the MDR-TB 
programme were highlighted in the review. The electronic data man-
agement system used to monitor the programme is a vertical system 
and data bypass districts. With limited opportunities for data valida-
tion or feedback at facility and district levels, there is little ownership 
of the data at facilities and data quality is poor. The low use of ID num-
bers as unique identifiers compromises attempts to monitor patients 
between different levels of care, facilities and laboratory services.
Laboratory service support for the MDR-TB programme was well 
managed. The introduction of the GeneXpert MTB/RIF diagnostic test 
reduced the time of MDR-TB diagnosis to <48 hours in >90% of the 
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cases reviewed. However, the capacity for second-line drug sensitivity 
testing is limited, and drug sensitivity testing for moxifloxacin, the 
key fluoroquinolone in both the current and shortened regimens, was 
not conducted.
While the shortened regimen is expected to reduce the proportion 
of patients who do not adhere to treatment, support for patients 
throughout the 9 - 12 months of the shortened regimen is still 
essential. Among patients interviewed during the review, 25% 
interrupted treatment for socioeconomic or treatment-related reasons. 
Community-level support was undermined by poor alignment of the 
decentralisation programme with the PHC re-engineering initiative.
Recommendations in light of the 
introduction of the shortened MDR-TB 
regimen
Based on the review, a number of recommendations relevant for 
effective implementation of both the shortened regimen and more 
widespread use of new and repurposed drugs were proposed.
The key recommendation for programme management and 
co-ordination was acceleration of decentralised and deinstitutionalised 
MDR-TB care through a more patient-centred approach. Recognising 
that different models of care are required to provide universal access to 
MDR-TB treatment, the review recommends that different packages, 
based on needs and local context, be piloted and scaled up. For 
each model of care, resource requirements at each level need to be 
clearly articulated, detailed costs determined and mechanisms to fund 
implementation determined.
The review recommended integration of the MDR-TB programme 
into other aspects of the health system. Integration of the MDR-TB 
programme with PHC re-engineering will facilitate patient support in 
the community from community health workers working in ward-based 
outreach teams.[18-19] At a PHC level, MDR-TB management must be 
integrated into all guidelines. And, to ensure correct implementation 
of guidelines, human resource needs have to be defined and facility 
level staff trained, supported and guided by clinicians and district and 
provincial TB co-ordinators. Some but not all provinces have provincial 
MDR-TB clinical management teams to provide clinical expertise, 
guidance and oversight on the clinical management of patients. With 
the introduction of new therapies, these teams need to be functioning 
optimally in all provinces to provide clinical oversight and support.
Implementation of the shortened regimen will require rapid 
identification of second-line drug resistance status with rapid feedback 
to clinicians. For optimal clinical care and adherence, the shortcomings 
in referral pathways, adverse event monitoring and pharmacovigilance 
reported in the review need to be addressed. Similarly, alignment of the 
health services to adaptations required by the shortened regimen, such 
as administration of the injectable 7 days a week, need to be addressed 
prior to implementation.
At a district level, MDR-TB treatment must be integrated into 
district-level services. To improve data quality, management and 
programme monitoring, the review recommended the alignment 
and incorporation of the MDR-TB data management system into the 
District Health Information System[20] and implementation of a unique 
patient identifier system.
Conclusion
The WHO-led review highlighted a range of measures to improve 
patient care and health system functioning. Central among these are 
strategies to accelerate decentralised and deinstitutionalised MDR-
TB care.
However, the management of MDR-TB is not simple, and the 
introduction of a new regimen and new and repurposed drugs brings 
additional complications. There is a risk that implementing new inter-
ventions will roll back the gains made through decentralisation to date. 
If these new interventions are to reach the greatest number of patients 
and improve patient outcomes, implementation of the review recom-
mendations and improved service delivery at centralised, decentralised 
and deinstitutionalised treatment sites are required. Increasing access 
to treatment for MDR-TB and improving patient outcomes will result 
in a greater proportion of successfully treated patients, reduced trans-
mission, and ultimately a reduction in the MDR-TB burden.
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